Monday, October 30, 2017 6:03:04 PM
I strongly believe Pluristem is on the cusp of major market exposure - what's quite amazing (taking into account their revolutionary technology) is that Plauristem is still very much under the radar. I also believe that big pharma is watching Stem Cell companies very closely, as this technology could potentially make a large percentage of traditional drug treatment obsolete - this is where the issue of partnerships becomes very interesting, but, at the same time quite problematic for the drug industry.
All in all, Pluristem's proprietary 3D generating and manufacturing capability is a game changer - I'm hopeful this recent infusion of capital will accelerate their R&D, leading to significant breakthroughs near term!
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM